08.45 – 09.00: Arrival
09.00 – 09.05: Welcome and Opening Remarks
Chair: Francis Jacob
09.05 – 09.15: Laurentz Schuhknecht (DBM) – “CRISPR meets metabolomics: A scalable platform for drug-target deconvolution”
09.15 – 09.25: Tobias Andermatt (DBM) – “Linking the tumor microenvironment to systemic inflammation and limited adaptive immunity as predictors of worse outcomes on immunotherapy in head and neck cancer”
09.25 – 09.35: Viviane Tschan (DBM, USB) – “Identification of novel therapeutic vulnerabilities in bladder cancer using patient-derived organoids”
09.35 – 09.45: Johanna Nimmerfroh (DBM) – “Sialic acid inhibits engager-mediated T cell activation”
09.45 – 10.15: Keynote Lecture n°1
Prof. Raffaella Santoro, Dept. of Molecular Mechanisms of Disease, University of Zürich “The nucleolus in healthy and disease states”
15’ discussion
10.30 – 11.00: Coffee Break and interactions with sponsors
Chair: Carolina Hager
11.05 – 11.15: Martino Bernasconi (DBM) – “Oncogenic signaling pathways activity landscaping for predictive modeling of drug efficacy and informing therapy decision in breast cancer”
11.15 – 11.25: Andreas Zigg (DBM) – “In vivo screening of TCR-based chimeric antigen receptors for improved anti-tumor functionality”
11.25 – 11.35: Kristy Ou (DBM, EMBL) – “Uncovering Early Drivers of Follicular Lymphoma Transformation through Integrated Single-Cell and Spatial Analysis”
11.35 – 11.45: Jack Kuipers (ETH Basel) – “Clone-level multi-modal prediction of tumour drug response”
11.45 – 12.05: Cross-disciplinary Talk
Dr. Inesa Fausch, Faculty of Law, University of Basel
“Bridging Innovation and Law: The Regulatory Future of Organoids in Oncology”
10’ discussion
12.15 – 13.45: Stand-up Lunch + interactions with sponsors
Chair: Clémentine Le Magnen
13.45 – 14.15: Keynote Lecture n°2
Dr. Adam Sharp, The Institute of Cancer Research (ICR), London “Targeting the intrinsic apoptosis pathway in lethal prostate cancer”
15’ discussion
14.30 – 14.40: Robin Dolgos (DBM, USB) – “A modular patient-derived organoid–xenograft platform reveals molecular and clinical trajectories of prostate cancer progression”
14.40 – 14.50: Tatjana Gremelspacher (DBM) – “Targeting oncogene-driven phosphatidic acid metabolism to treat acute myeloid leukaemia”
14.50 – 15.00: Maria Rafaeva (DBM) – “Dissecting the effect of the microenvironment in the transition from breast cancer dormancy to outgrowth in brain metastasis”
15.00 – 15.20: Patient Advocate and Physician discussion
10’ discussion
15.30 – 16.00: Coffee Break and interactions with sponsors
Chair: Petya Apostolova
16.00 – 16.10: Sebastian Bors (DBM) – “Finding weaknesses in cancer via genome-scale mapping of transcription factor mediated metabolic rewiring”
16.10 – 16.20: Jana Petr (ETH Basel) – “Visualizing medulloblastoma invasion dynamics in organotypic cerebellar slices”
16.20 – 16.30: Juan Jauregui (DBM) – “Chemotherapy-derived replication stress drives abortive and accelerated red blood cell differentiation”
16.30 – 16.40: Javier Pareja (DBM) – “Penk-expressing Tregs drive proinflammatory DCs and enhance tumour control”
16.40 – 16.50: Zora Baumann (Novartis) – “Unraveling prostate cancer bone metastasis biology using a translational organoid system”
16.50: Concluding remarks, end of the OncoDay 2026
17.00 – 18.00: Apero
Kleiner Hörsaal, ZLF, Department of Biomedicine
Hebelstrasse 20, 4031 Basel
We look forward to welcoming you to our event. By filling in these details we can better plan your participation. You will receive a copy of the request by e-mail.
This website uses cookies to ensure you get the best experience on our website. Learn more